Salvage Ovarian FANG™ Vaccine + Bevacizumab
NCT01551745
Completed
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking. Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 4 weeks and bevacizumab 10 mg/kg intravenously every 2 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2021
Locations: Mary Crowley Cancer Research Centers, Dallas, Texas
Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Register for Updates
Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation
NCT03889158
Terminated
This study focuses on whether high cardiorespiratory fitness in older adults has a protective effect on the vascular response to acute inflammation in comparison to low-fit older and young adults.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/15/2021
Locations: Integrative Physiology Laboratory, Suite 158, Chicago, Illinois
Conditions: Aging, Inflammation
Register for Updates
Early Immune Responses to Vaccination - A Substudy to HVTN 205
NCT00908323
Completed
HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is to better understand how a person's immune system responds to vaccines, particularly HIV vaccines. More specifically, researchers will determine whether early responses in the immune system help predict strong and long-lasting immunity.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama Vaccine CRS, Birmingham, Alabama +2 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
NCT01571960
Completed
This study will test the safety and immune responses of a prime-boost regimen of two HIV vaccines- a DNA vaccine followed by a modified vaccinia Ankara (MVA) vaccine- in healthy, HIV-uninfected, vaccinia-naive adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama CRS, Birmingham, Alabama +3 locations
Conditions: HIV Infections
Register for Updates
Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins
NCT01054872
Completed
The purpose of this study is to examine the role of genetics in determining the immune response to an HIV vaccine in pairs of HIV-uninfected twins.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts +1 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
NCT02207920
Completed
This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with HIV.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California +6 locations
Conditions: HIV Infections
Register for Updates
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
NCT00865566
Terminated
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men. NOTES: As of April 2013, all vaccinations in this study have been stopped. As of June 2017, this study has been closed.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama CRS, Birmingham, Alabama +21 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
NCT01578889
Completed
Some vaccines may work better when given together with another substance known as an adjuvant or when given with an experimental procedure called electroporation (EP). EP is a method where an electric pulse is administered to the same muscle where the vaccine injection is given. The addition of the adjuvant to the vaccine and the delivery with EP may increase a person's immune response to the vaccine. Combination approaches such as a DNA vaccine followed by live vector boost may also increase a... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Columbia P&S CRS, New York, New York +4 locations
Conditions: HIV Infections
Register for Updates
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
NCT00801697
Completed
This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama CRS, Birmingham, Alabama +9 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
NCT01783977
Completed
NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped. Currently, there are no vaccines approved for the prevention of HIV infection, but there are many clinical trials taking place that are studying experimental HIV vaccines. The purpose of this study is to evaluate the safety and tolerability of three different HIV vaccine schedules in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama CRS, Birmingham, Alabama +7 locations
Conditions: HIV Infections
Register for Updates
HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants
NCT00125970
Completed
The purpose of the study is to determine the safety of and immune response to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Alabama Vaccine CRS, Birmingham, Alabama +11 locations
Conditions: HIV Infections
Register for Updates
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
NCT01479296
Completed
The purpose of this study is to evaluate the immune response to the Vaccine Research Center (VRC) rAd5 HIV vaccine when the vaccine components are administered in three different ways, in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California +7 locations
Conditions: HIV Infections
Register for Updates